A new study identified chaperone‑mediated autophagy as essential for glioblastoma stem cell maintenance and showed that its inhibition both depletes stem‑like cells and reinvigorates anti‑tumor immune responses. The authors combined molecular perturbation with immune profiling to link autophagy blockade to enhanced tumor immunogenicity. Glioblastoma stem cells are implicated in therapy resistance and recurrence; targeting a cellular recycling pathway that supports their survival offers a distinct mechanism to sensitize tumors. The findings point to potential combination trials pairing autophagy pathway inhibitors with immunotherapies for aggressive brain tumors, subject to safety evaluation in CNS contexts.